CN113845691B - Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof - Google Patents
Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof Download PDFInfo
- Publication number
- CN113845691B CN113845691B CN202111146115.8A CN202111146115A CN113845691B CN 113845691 B CN113845691 B CN 113845691B CN 202111146115 A CN202111146115 A CN 202111146115A CN 113845691 B CN113845691 B CN 113845691B
- Authority
- CN
- China
- Prior art keywords
- cellulose
- dimensional
- based porous
- antibacterial material
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002678 cellulose Polymers 0.000 title claims abstract description 154
- 239000001913 cellulose Substances 0.000 title claims abstract description 154
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 111
- 239000000463 material Substances 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000004005 microsphere Substances 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003513 alkali Substances 0.000 claims abstract description 20
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 20
- 239000004202 carbamide Substances 0.000 claims abstract description 20
- 239000002608 ionic liquid Substances 0.000 claims abstract description 20
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- -1 alkyl dialdehyde Chemical compound 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 238000003980 solgel method Methods 0.000 claims abstract description 6
- 239000003054 catalyst Substances 0.000 claims abstract description 3
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 230000000845 anti-microbial effect Effects 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims description 11
- 229960002064 kanamycin sulfate Drugs 0.000 claims description 11
- 239000007790 solid phase Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003929 acidic solution Substances 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960000318 kanamycin Drugs 0.000 claims description 8
- 229930027917 kanamycin Natural products 0.000 claims description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 8
- 229930182823 kanamycin A Natural products 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 7
- 229920000742 Cotton Polymers 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940015043 glyoxal Drugs 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001131 Pulp (paper) Polymers 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- LEMKWEBKVMWZDU-UHFFFAOYSA-N nonanedial Chemical compound O=CCCCCCCCC=O LEMKWEBKVMWZDU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 19
- 230000000968 intestinal effect Effects 0.000 abstract description 16
- 241000894006 Bacteria Species 0.000 abstract description 11
- 210000004211 gastric acid Anatomy 0.000 abstract description 11
- 239000011148 porous material Substances 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000003911 water pollution Methods 0.000 abstract description 2
- 230000001580 bacterial effect Effects 0.000 description 19
- 239000007788 liquid Substances 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 241000607142 Salmonella Species 0.000 description 8
- 229920001661 Chitosan Polymers 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 239000006916 nutrient agar Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000014670 detection of bacterium Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- WTHDKMILWLGDKL-UHFFFAOYSA-N urea;hydrate Chemical compound O.NC(N)=O WTHDKMILWLGDKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/05—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur
- C08B15/06—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur containing nitrogen, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
- C08J2301/08—Cellulose derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a two-dimensional or three-dimensional cellulose-based porous antibacterial material, which is prepared by taking cellulose as a main material, acid as a catalyst, alkyl dialdehyde as a cross-linking agent, grafting antibiotics through a chemical method, dissolving a sample in a low-temperature alkali/urea solution or ionic liquid, and adopting a sol-gel method. The cellulose-based antibacterial material is insoluble in water and conventional organic solvents, and effectively reduces the problem of water pollution caused by easy dissolution of antibiotics. The cellulose-based antibacterial material has obvious inhibition effect on gram-positive bacteria and gram-negative bacteria, is a stable, efficient, broad-spectrum and edible antibacterial agent, and has extremely low cytotoxicity. The two-dimensional cellulose-based antibacterial porous material and the three-dimensional cellulose-based antibacterial microsphere have good gastric acid resistance, can be used as an oral antibacterial material, and can directly inhibit intestinal bacteria after gastric acid passing.
Description
Technical Field
The invention belongs to the field of functional materials, relates to a two-dimensional or three-dimensional cellulose-based porous antibacterial material and a preparation method thereof, and in particular relates to a grafted modified cellulose-based antibacterial material and a preparation method thereof.
Background
It is well known that conventional medical procedures (e.g., surgery, intensive care medicine, and infection treatment) are not separated from antibiotics. However, the abuse of antibiotics results in the development of resistance to a large number of pathogenic bacteria, which severely jeopardizes human life health. Researchers predict that by 2050, antibiotic resistance will lead to death in more than 1000 tens of thousands of people, exceeding the mortality rate of cancer. Therefore, the development of a novel, efficient and safe antibacterial material different from the traditional antibiotics has great market value.
Chitosan-based antibacterial agents (CAMs), particularly chitosan micro-and nanoparticles, are considered as one of the antibiotic substitutes with application prospects. CAMs exhibit potent broad-spectrum antimicrobial activity against a variety of pathogens, do not cause toxicity in vitro and in cell lines, and produce little resistance to antibiotics for long periods of time. However, CAMs have relatively low antimicrobial activity against a variety of pathogens compared to antibiotics.
Cellulose is an inexhaustible natural polymer, has a large number of modifiable hydroxyl sites, is nontoxic and has good biocompatibility, and is stable in most solvents. Thus, cellulose is considered as an excellent host material for novel antibacterial materials. In recent years, various novel cellulose-based antibacterial materials, such as quaternized cellulose antibacterial materials, metal oxide/cellulose antibacterial materials, chitosan/cellulose antibacterial materials, and the like, have been studied. These cellulose-based antibacterial materials exhibit a remarkable inhibitory effect against many pathogenic bacteria by modifying functional antibacterial molecules or mixing with antibacterial materials. However, most of the cellulose antibacterial agents are mainly used for environmental sterilization because of the presence of quaternized functional molecules and metal oxides. In the chitosan/cellulose antibacterial material, the antibacterial property mainly comes from chitosan. The problem of low antimicrobial activity of chitosan against pathogens also limits the use of chitosan/cellulose materials.
Therefore, if a cellulose-based antibacterial material which is environment-friendly, stable, high in broad-spectrum bacteriostasis and low in cost can be developed, the cellulose-based antibacterial material has great market value.
Disclosure of Invention
The invention aims to provide an environment-friendly, stable, broad-spectrum and low-cost cellulose-based antibacterial material. The cellulose-based antibacterial material takes cellulose as a main material, and antibacterial components such as kanamycin sulfate, kanamycin hydrochloride and the like are grafted on hydrophilic water-insoluble cellulose through an acetal reaction, so that a powdery fiber-based antibacterial material is prepared; then, in order to further improve the specific surface area of the cellulose-based antibacterial material, dissolving the powdery cellulose-based antibacterial material in an alkali/urea aqueous solution or an ionic liquid, and preparing the two-dimensional porous cellulose-based antibacterial material and the three-dimensional porous cellulose-based antibacterial microsphere by a sol-gel method.
The invention aims at realizing the following technical scheme:
a two-dimensional or three-dimensional cellulose-based porous antibacterial material is prepared from cellulose serving as a main material, acid serving as a catalyst, alkyl dialdehyde serving as a cross-linking agent through grafting antibiotics by a chemical method, dissolving a sample in a low-temperature alkali/urea solution or ionic liquid, and preparing the two-dimensional cellulose-based porous antibacterial material or the cellulose-based porous antibacterial microsphere by a sol-gel method.
The cellulose is one or more of alpha-cellulose, cotton cellulose and paper pulp. The purity of cellulose in the pulp is more than 85%.
The antibiotics are kanamycin hydrochloride and kanamycin sulfate.
The mass ratio of the cellulose to the antibiotics is 1:0.001-1:1.
The alkyl dialdehyde is one or more of glutaraldehyde, glyoxal, hexanedial and nonanedial.
The mass ratio of the cellulose to the alkyl dialdehyde is 1:0.01-1:1.
The acid is hydrochloric acid, sulfuric acid, acetic acid solution and phosphoric acid solution with the concentration of 0.1-1M; the mass-volume ratio of the cellulose to the acid is 1:1-500 g/mu L.
The temperature of the low-temperature alkali/urea solution is less than or equal to-20 ℃, and the mass ratio of alkali to urea to water is 3-12:5-18:85-70; the ionic liquid is [ BmimCl ] ionic liquid.
Another object of the present invention is to provide a method for preparing the two-dimensional or three-dimensional cellulose-based porous antibacterial material, comprising the steps of:
step (1), dispersing cellulose and antibiotics in water, adding an acidic solution, and uniformly stirring;
adding alkyl dialdehyde into the solution obtained in the step (1) under the light-shielding condition, and stirring for 1-24 h at the temperature of 10-50 ℃;
filtering the sample after the reaction in the step (3) and the step (2), collecting particles, washing with water, and drying in vacuum;
and (4) dissolving the sample obtained in the step (3) in a low-temperature alkali/urea solution or an ionic liquid, and preparing the two-dimensional cellulose-based porous antibacterial material or the cellulose-based porous antibacterial microsphere by adopting a sol-gel method.
In the step (1), the acid solution is hydrochloric acid, sulfuric acid, acetic acid solution and phosphoric acid solution with the concentration of 0.1-1M; the mass-volume ratio of the cellulose to the acidic solution is 1:1-500 g/mu L.
In the step (4), the dosage ratio of the sample obtained in the step (3) to the low-temperature alkali/urea solution or the ionic liquid is 1:10-1:40 g/mL.
When the cellulose-based porous antibacterial material is a two-dimensional cellulose-based porous antibacterial material, dissolving the sample obtained in the step (3) in a low-temperature alkali/urea solution or ionic liquid, soaking the obtained solution (sol) in an acidic solution or an organic solvent, performing phase transition, converting a liquid phase into a solid phase, collecting the solid phase, washing the solid phase with water to be neutral, and performing vacuum drying or freeze-drying to constant weight at 20-60 ℃ to obtain the two-dimensional cellulose-based porous antibacterial material; wherein the acidic solution is acetic acid, hydrochloric acid or phosphoric acid, and the organic solvent is ethanol, methanol, glycol or acetone; or dissolving the sample obtained in the step (3) in low-temperature alkali/urea solution or ionic liquid, sealing, and performing heat treatment at 50 ℃ for at least 24 hours to obtain cellulose-based two-dimensional gel, washing the cellulose-based two-dimensional gel to be neutral by using an acidic aqueous solution or pure water, and performing vacuum drying or freeze-drying to be constant weight at 20-60 ℃ to obtain the two-dimensional cellulose-based porous antibacterial material.
When the cellulose-based porous antibacterial material is a cellulose-based porous antibacterial microsphere, dissolving the sample obtained in the step (3) in a low-temperature alkali/urea solution or an ionic liquid, dripping the obtained solution into a solvent, collecting a solid phase, washing with water to be neutral, and carrying out vacuum drying or freeze-drying at 20-60 ℃ to constant weight to obtain the cellulose-based porous antibacterial microsphere; wherein the solvent is acetic acid, hydrochloric acid, phosphoric acid or other acidic solution or ethanol, methanol, glycol, acetone or other polar organic solvent.
The invention also aims to provide the application of the two-dimensional or three-dimensional cellulose-based porous antibacterial material in preparing an oral antibacterial preparation.
The invention has the beneficial effects that:
compared with the prior art that cellulose is modified by aldehyde and then grafted with antibacterial materials, the cellulose is not required to be modified before grafting, but cellulose and kanamycin are directly grafted by glutaraldehyde, and linked sites are hydroxyl groups of cellulose and hydroxyl groups of kana, so that the reaction is simpler and faster.
The cellulose-based antibacterial material is insoluble in water and conventional organic solvents, and effectively reduces the problem of water pollution caused by easy dissolution of antibiotics.
The cellulose-based antibacterial material has obvious inhibition effect on gram-positive bacteria and gram-negative bacteria, is a stable, efficient, broad-spectrum and edible antibacterial agent, and has extremely low cytotoxicity. The two-dimensional cellulose-based antibacterial porous material and the three-dimensional cellulose-based antibacterial microsphere have good gastric acid resistance, can be used as an oral antibacterial material, and can directly inhibit intestinal bacteria after gastric acid passing.
The three-dimensional cellulose-based antibacterial microsphere or the two-dimensional cellulose-based antibacterial porous material has a porous structure, has a large specific surface area and BSA adsorption capacity, and can fix medicines, proteins and the like.
Drawings
FIG. 1 is a graph showing the inhibition of E.coli by the cellulose-based antibacterial material of example 1 directly observed in a plate count method. A) Original bacterial liquid; b) Inhibition of E.coli by alpha-cellulose; c) Inhibition of E.coli by cellulose-based antibacterial materials.
FIG. 2 is a graph showing the inhibition of Staphylococcus aureus by the cellulose-based antibacterial material of example 2 directly observed in a plate count method. A) Original bacterial liquid; b) Inhibition of staphylococcus aureus by cotton cellulose; c) Inhibition of staphylococcus aureus by cellulose-based antibacterial materials.
FIG. 3 is a graph showing the inhibition of Salmonella by the cellulose-based antibacterial material of example 3 directly observed in a plate count method. A) Original bacterial liquid; b) Inhibition of salmonella by pulp; c) Inhibition of salmonella by cellulose-based antimicrobial materials.
FIG. 4 is a microstructure of the two-dimensional cellulose-based porous antimicrobial material of example 4.
Fig. 5 is a bacterial growth curve of the two-dimensional cellulose-based multi-Kong Yijun material of example 4 in intestinal fluid.
FIG. 6 is a microstructure of the cellulose-based porous antimicrobial microspheres of example 5.
FIG. 7 is a graph showing the bacterial growth in intestinal fluid of the cellulose-based porous antimicrobial microspheres of example 5.
Fig. 8 is a safety inspection result of the cellulose-based porous antimicrobial microsphere of example 5.
Detailed Description
The technical scheme of the invention is further described by the following specific examples.
Example 1
5g of alpha-cellulose and 0.058g of kanamycin sulfate were dispersed in 10mL of water, 5. Mu.L of 0.1M hydrochloric acid was added dropwise, and stirring was carried out for 30 minutes; dropwise adding 0.05g glutaraldehyde under the dark condition, and stirring for 2 hours at normal temperature; filtering, collecting particles, removing the incompletely reacted kanamycin sulfate by a large amount of pure water, and vacuum drying at 60 ℃ for 5 hours to obtain the kanamycin sulfate grafted cellulose-based antibacterial material.
The inhibition of E.coli (gram-negative bacteria) by the cellulose-based antibacterial material of this example was examined: inoculating Escherichia coli into liquid culture medium (LB medium), culturing at 37deg.C until bacterial liquid OD 600 =1.39, i.e. the original bacterial liquid. 1mL of the original bacterial liquid is taken, 50mg of the cellulose-based antibacterial material or alpha-cellulose of the embodiment is added, the mixture is vibrated for 3 hours at 37 ℃, a plate is coated, and the number of the escherichia coli growing on a nutrient agar plate is detected, and the result is shown in figure 1. The method shows that after the cellulose-based antibacterial material is added into the original bacterial liquid, the number of the escherichia coli growing on the nutrient agar plate is obviously reduced. The following is indicated: the kanamycin sulfate grafted cellulose-based antibacterial material has excellent escherichia coli inhibition capability.
Example 2
5g of cotton cellulose and 5.8g of kanamycin hydrochloride are dispersed in 50mL of water, 2.5mL of 0.1M acetic acid aqueous solution is added dropwise, and stirring is carried out for 30 minutes; dropwise adding 5g of glyoxal under the condition of avoiding light, and stirring for 6 hours at normal temperature; the particles were collected by filtration, and the unreacted kanamycin hydrochloride was removed by a large amount of pure water, and dried in vacuo at 40℃for 10 hours to give a kanamycin hydrochloride grafted cellulose-based antibacterial material, the adsorption amount of BSA was 162.5mg/g.
The inhibition of staphylococcus aureus (gram positive bacteria) by the cellulose-based antibacterial material of this example was examined: inoculating Staphylococcus aureus into liquid culture medium (LB culture medium), culturing at 37deg.C until bacterial liquid OD 600 =1.18, i.e. the original bacterial liquid. 1mL of the original bacterial liquid is taken, 50mg of the cellulose-based antibacterial material or cotton cellulose of the embodiment is added, the mixture is vibrated for 3 hours at 37 ℃, a plate is coated, and the number of staphylococcus aureus growing on a nutrient agar plate is detected, and the result is shown in figure 2. The display shows that the fiber is added into the original bacterial liquidAfter the element-based antibacterial material, the number of staphylococcus aureus growing on the nutrient agar plate is obviously reduced. The following is indicated: the kanamycin hydrochloride grafted cellulose-based antibacterial material has excellent staphylococcus aureus inhibition capability.
Example 3
5g of pulp (free of water, cellulose content > 85%) and 2g of kanamycin sulfate were dispersed in 20mL of water, 500. Mu.L of 0.5M phosphoric acid aqueous solution was added dropwise, and stirred for 1 hour; 3g of glyoxal is added dropwise under the condition of light shielding, and stirring is carried out for 12 hours at normal temperature; filtering, collecting particles, removing the incompletely reacted kanamycin sulfate by a large amount of pure water, and vacuum drying at normal temperature for 24 hours to obtain the kanamycin sulfate grafted cellulose-based antibacterial material.
The inhibition of salmonella (gram-negative bacteria) by the cellulose-based antimicrobial material of this example was examined: inoculating Salmonella into liquid culture medium (LB medium), culturing at 37deg.C to reach solution OD 600 =2.19. 1mL of the original bacterial liquid is taken, 50mg of the cellulose-based antibacterial material or paper pulp of the embodiment is added, the mixture is vibrated for 3 hours at 37 ℃, a plate is coated, and the number of salmonella grown on a nutrient agar plate is detected, and the result is shown in figure 3. The method shows that after the cellulose-based antibacterial material is added into the original bacterial liquid, the number of salmonella grown on the nutrient agar plate is obviously reduced. The following is indicated: the kanamycin sulfate grafted cellulose-based antibacterial material has excellent salmonella inhibition capability.
Example 4
Taking 5g of the cellulose-based antibacterial material prepared in the example 1, dissolving in 100mL of an alkali/urea water system (prepared by sodium hydroxide, urea and water according to a mass ratio of 7:12:81) at a temperature of-20 ℃ to obtain a cellulose-based antibacterial material solution; then the solution is soaked in 1M acetic acid aqueous solution to obtain the two-dimensional cellulose-based porous antibacterial material (figure 4), the outer surface and the inner surface of the two-dimensional cellulose-based porous antibacterial material both contain a large number of pore structures, and the adsorption quantity of BSA reaches 217.3mg/g.
50mg of the two-dimensional cellulose-based porous antibacterial material of the embodiment is taken and soaked in 1mL of simulated gastric acid (artificial gastric juice (source leaf organism), and the manufacturer is Shanghai source leaf biotechnology Co., ltd., product number is R30388) to vibrate3 hours, take out and transfer to 1mL simulated intestinal fluid (artificial small intestinal fluid (Source leaf organism), manufacturer: shanghai Source leaf Biotechnology Co., ltd., product number: R22156); adding Escherichia coli original bacterial liquid 100 μl (OD of original bacterial liquid) 600 =1.39), shaking at 37 ℃ for 6 hours. OD detection of bacteria-containing intestinal juice per hour 600 Values (fig. 5). Experimental results show that the two-dimensional cellulose-based porous antibacterial material still has good escherichia coli inhibition capability after being soaked in gastric acid for 3 hours. OD in intestinal juice containing two-dimensional cellulose-based porous antibacterial material 600 The values were lower than those of the bacteria-containing intestinal juice (without cellulose material) containing the two-dimensional porous cellulose material of comparative example 1. It can be seen that the two-dimensional cellulose-based porous antibacterial material has good gastric acidity resistance. The two-dimensional cellulose-based porous antibacterial material can be used as an oral antibacterial material, and intestinal bacteria can be directly inhibited after gastric acid is passed.
Comparative example 1
5g of alpha-cellulose was taken and dissolved in 100mL of an alkali/urea aqueous system at-20 ℃ (same as in example 4), and then the above solution was immersed in a 1M aqueous acetic acid solution to obtain a two-dimensional porous cellulose material.
Example 5
Taking 5g of the cellulose-based antibacterial material prepared in example 2, and dissolving the cellulose-based antibacterial material in 100mL of [ BmimCl ] ionic liquid to obtain a cellulose-based antibacterial material solution; the above cellulose-based antibacterial material solution (volume 1 μl) was then added dropwise to ethanol (volume 1 mL), the solid phase was collected, washed with water to neutrality, and dried under vacuum at 20deg.C to constant weight to obtain three-dimensional cellulose-based porous antibacterial microspheres (FIG. 6). The cellulose-based porous antibacterial microsphere is in a standard sphere shape, the surface of the cellulose-based porous antibacterial microsphere contains a large number of hole structures, the size of the microsphere is 1-10 mu m, and the BSA adsorption capacity of the three-dimensional cellulose-based porous antibacterial microsphere reaches 429.2mg/g.
50mg of the three-dimensional cellulose-based porous antibacterial microspheres of the embodiment are taken, soaked in simulated gastric acid (same as embodiment 4) and oscillated for 5 hours, taken out and transferred into simulated intestinal juice (same as embodiment 4); 100. Mu.L of the original bacterial liquid of staphylococcus aureus (OD of the original bacterial liquid) is added 600 =1.18), shaking at 37 ℃ for 6 hours. OD detection of bacteria-containing intestinal juice per hour 600 Values (fig. 7). Experimental resultsThe three-dimensional cellulose-based porous antibacterial material still has good staphylococcus aureus inhibition ability after 3 hours of gastric acid soaking. OD in intestinal juice containing three-dimensional cellulose-based porous antibacterial microspheres 600 The values were far lower than the bacteria-containing intestinal fluid (without cellulose material) and the bacteria-containing intestinal fluid containing the three-dimensional cellulose microspheres of comparative example 2. The three-dimensional cellulose-based porous antibacterial microspheres have good gastric acid resistance, can be used as an oral antibacterial material, and can directly inhibit intestinal bacteria after gastric acid passing.
Culture medium for Vero cells: dulbecco's Modified Eagle Medium (DMEM) medium: 10% of fetal bovine serum, 1% of antibiotic solution and 10% of amino acid.
The Vero cells cultured in the cell bottle are inoculated in a 96-well plate after being digested, and are placed in a 37 ℃ incubator for culturing for 24 hours; 200. Mu.L of the three-dimensional cellulose-based porous antimicrobial microsphere aqueous dispersion of the present example (200. Mu.g/mL, 100. Mu.g/mL, 50. Mu.g/mL, 25. Mu.g/mL, 12.5. Mu.g/mL, 0. Mu.g/mL) at different concentrations was added to the above-mentioned culture plate, and incubated in an incubator at 37℃for 6 hours. To each well after the above treatment, 10. Mu.L of CCK-8 solution was added, and incubated at 37℃for 1 hour, and OD450 values were measured (FIG. 8). The result shows that when the content of the three-dimensional cellulose-based antibacterial microsphere reaches 50 mug/mL, the cell survival rate is 90%, and the three-dimensional cellulose-based antibacterial microsphere has extremely low cytotoxicity.
Comparative example 2
5g of cotton cellulose is taken and dissolved in 100mL of [ BmimCl ] ionic liquid, then the solution (volume 1 mu L) is dropwise added into ethanol (volume 1 mL), the solid phase is collected, washed to be neutral by water, and dried to constant weight at 20 ℃ in vacuum, thus obtaining the three-dimensional cellulose microsphere.
Claims (8)
1. A two-dimensional or three-dimensional cellulose-based porous antimicrobial material, characterized in that: the cellulose-based porous antibacterial material is prepared by taking cellulose as a main material, acid as a catalyst, alkyl dialdehyde as a cross-linking agent, grafting antibiotics through a chemical method, dissolving a sample in a low-temperature alkali/urea solution or ionic liquid, and preparing a two-dimensional cellulose-based porous antibacterial material or cellulose-based porous antibacterial microsphere by adopting a sol-gel method;
the antibiotics are kanamycin hydrochloride or kanamycin sulfate;
the mass ratio of the cellulose to the antibiotics is 1:0.001-1:1;
when the cellulose-based porous antibacterial material is a two-dimensional cellulose-based porous antibacterial material, dissolving a sample in a low-temperature alkali/urea solution or ionic liquid, soaking the obtained solution in an acidic solution or an organic solvent, performing phase transition, converting from a liquid phase to a solid phase, collecting the solid phase, washing with water to be neutral, and performing vacuum drying or freeze drying to constant weight at 20-60 ℃ to obtain the two-dimensional cellulose-based porous antibacterial material; wherein the acidic solution is acetic acid, hydrochloric acid or phosphoric acid, and the organic solvent is ethanol, methanol, glycol or acetone; or dissolving the sample in low-temperature alkali/urea solution or ionic liquid, sealing, and performing heat treatment at 50 ℃ for at least 24 hours to obtain cellulose-based two-dimensional gel, washing the cellulose-based two-dimensional gel to be neutral by using acidic aqueous solution or pure water, and performing vacuum drying or freeze-drying to be constant weight at 20-60 ℃ to obtain the two-dimensional cellulose-based porous antibacterial material;
when the cellulose-based porous antibacterial material is a cellulose-based porous antibacterial microsphere, dissolving a sample in a low-temperature alkali/urea solution or ionic liquid, dripping the obtained solution into a solvent, collecting a solid phase, washing with water to be neutral, and carrying out vacuum drying or freeze-drying to constant weight at 20-60 ℃ to obtain the cellulose-based porous antibacterial microsphere; wherein the solvent is acetic acid, hydrochloric acid, phosphoric acid, ethanol, methanol, glycol or acetone;
the temperature of the low-temperature alkali/urea solution is less than or equal to-20 ℃, and the mass ratio of alkali to urea to water is 3-12:5-18:85-70; the ionic liquid is [ BmimCl ] ionic liquid.
2. The two-or three-dimensional cellulose-based porous antimicrobial material according to claim 1, wherein: the cellulose is one or more of alpha-cellulose, cotton cellulose and paper pulp.
3. The two-or three-dimensional cellulose-based porous antimicrobial material according to claim 1, wherein: the alkyl dialdehyde is one or more of glutaraldehyde, glyoxal, hexanedial and nonanedial.
4. A two-or three-dimensional cellulose-based porous antimicrobial material according to claim 1 or 3, characterized in that: the mass ratio of the cellulose to the alkyl dialdehyde is 1:0.01-1:1.
5. The two-or three-dimensional cellulose-based porous antimicrobial material according to claim 1, wherein: the acid is hydrochloric acid, sulfuric acid, acetic acid solution or phosphoric acid solution with the concentration of 0.1-1M; the mass-volume ratio of the cellulose to the acid is 1:1-500 g/. Mu.L.
6. A method of preparing a two-or three-dimensional cellulose-based porous antimicrobial material according to claim 1, characterized in that: the method comprises the following steps:
step (1), dispersing cellulose and antibiotics in water, adding an acidic solution, and uniformly stirring;
adding alkyl dialdehyde into the solution obtained in the step (1) under the light-shielding condition, and stirring for 1-24 h at the temperature of 10-50 ℃;
filtering the sample obtained by the reaction in the step (3) and the step (2), collecting particles, washing with water, and drying in vacuum;
and (4) dissolving the sample obtained in the step (3) in a low-temperature alkali/urea solution or an ionic liquid, and preparing the two-dimensional cellulose-based porous antibacterial material or the cellulose-based porous antibacterial microsphere by adopting a sol-gel method.
7. The method of preparing a two-or three-dimensional cellulose-based porous antimicrobial material according to claim 6, wherein: in the step (4), the dosage ratio of the sample obtained in the step (3) to the low-temperature alkali/urea solution or the ionic liquid is 1:10-1:40 g/mL.
8. Use of the two-or three-dimensional cellulose-based porous antibacterial material of claim 1 for the preparation of an oral bacteriostatic formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111146115.8A CN113845691B (en) | 2021-09-28 | 2021-09-28 | Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111146115.8A CN113845691B (en) | 2021-09-28 | 2021-09-28 | Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113845691A CN113845691A (en) | 2021-12-28 |
| CN113845691B true CN113845691B (en) | 2024-03-22 |
Family
ID=78980547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111146115.8A Active CN113845691B (en) | 2021-09-28 | 2021-09-28 | Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113845691B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151895A (en) * | 1996-08-02 | 1997-06-18 | 高景星 | Body-compatible antiseptic and antiphlogitic bleeding-stopping dressing and its prepn |
| CN1811410A (en) * | 2005-01-27 | 2006-08-02 | 北京大学 | Affinity chromatograph filling and producing process and application thereof |
| CN101258196A (en) * | 2005-06-29 | 2008-09-03 | 阿拉巴马大学 | Ionic liquid reconstituted cellulose composites as solid support matrices |
| CN107028896A (en) * | 2017-04-26 | 2017-08-11 | 盐城工业职业技术学院 | A kind of carried medicine sustained-release system and medicine |
| WO2018002446A1 (en) * | 2016-06-30 | 2018-01-04 | Xylocel Oy | Porous cellulose structure |
| CN109414432A (en) * | 2016-06-14 | 2019-03-01 | 港大科桥有限公司 | Antimicrobe compound and its application method |
| CN110087633A (en) * | 2016-12-15 | 2019-08-02 | 芬欧汇川集团 | The method of the dry hydrogel comprising nanometer fibril cellulose and the hydrogel of the drying comprising nanometer fibril cellulose |
| CN110229351A (en) * | 2019-06-19 | 2019-09-13 | 南京工业职业技术学院 | A kind of preparation method and application of anti-bacterial fibre hydrogel |
| CN110314242A (en) * | 2018-11-09 | 2019-10-11 | 上海长征医院 | A kind of preparation method and its usage of the antibiotic composite hydrogel of controlled release |
-
2021
- 2021-09-28 CN CN202111146115.8A patent/CN113845691B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151895A (en) * | 1996-08-02 | 1997-06-18 | 高景星 | Body-compatible antiseptic and antiphlogitic bleeding-stopping dressing and its prepn |
| CN1811410A (en) * | 2005-01-27 | 2006-08-02 | 北京大学 | Affinity chromatograph filling and producing process and application thereof |
| CN101258196A (en) * | 2005-06-29 | 2008-09-03 | 阿拉巴马大学 | Ionic liquid reconstituted cellulose composites as solid support matrices |
| CN109414432A (en) * | 2016-06-14 | 2019-03-01 | 港大科桥有限公司 | Antimicrobe compound and its application method |
| WO2018002446A1 (en) * | 2016-06-30 | 2018-01-04 | Xylocel Oy | Porous cellulose structure |
| CN110087633A (en) * | 2016-12-15 | 2019-08-02 | 芬欧汇川集团 | The method of the dry hydrogel comprising nanometer fibril cellulose and the hydrogel of the drying comprising nanometer fibril cellulose |
| CN107028896A (en) * | 2017-04-26 | 2017-08-11 | 盐城工业职业技术学院 | A kind of carried medicine sustained-release system and medicine |
| CN110314242A (en) * | 2018-11-09 | 2019-10-11 | 上海长征医院 | A kind of preparation method and its usage of the antibiotic composite hydrogel of controlled release |
| CN110229351A (en) * | 2019-06-19 | 2019-09-13 | 南京工业职业技术学院 | A kind of preparation method and application of anti-bacterial fibre hydrogel |
Non-Patent Citations (1)
| Title |
|---|
| 刘志明.《木质纤维的纳米纤丝化和凝胶化及吸附性能研究》.哈尔滨工程大学出版社,2018,第3-6页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113845691A (en) | 2021-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gorgieva et al. | Bacterial cellulose: Production, modification and perspectives in biomedical applications | |
| CN113813396B (en) | Kanamycin grafted cellulose-based antibacterial material and preparation method thereof | |
| CN110117369B (en) | Antibacterial adhesive conductive hydrogel and preparation method and application thereof | |
| CN109207384A (en) | modified yeast cell wall and its preparation method and application | |
| CN111154149A (en) | Hydrogel and preparation method and dressing thereof | |
| CN109316824A (en) | A kind of preparation method of Quaternary Ammonium Salt of Chitosan polyvinyl alcohol antimicrobial filtering composite material | |
| CN110747534A (en) | Antibacterial polysaccharide fiber material and preparation method thereof | |
| CN113248632A (en) | Multifunctional traditional Chinese medicine organic acid grafted chitosan quaternary ammonium salt broad-spectrum antibacterial agent and preparation method thereof | |
| CN112494713A (en) | Probiotic-combined oxidized bletilla striata polysaccharide-chitosan composite hydrogel and preparation method and application thereof | |
| CN110003359A (en) | A kind of hydrophily high substituted degree modification of chitosan preparation method and applications | |
| CN114392388A (en) | Hydrogel composition and application thereof | |
| CN113367157A (en) | Preparation method of flower-like silver/lignin composite antibacterial particles | |
| CN104740672A (en) | Chitosan gold nano-particle compound as well as preparation method and application thereof | |
| CN110152055B (en) | Functional drug sustained-release medical dressing constructed by alginic acid aminated derivative/bacterial cellulose nanocrystalline composite gel | |
| CN116078175A (en) | Carbon nitride-polydopamine-nano silver antibacterial composite membrane based on chitosan | |
| Alemu et al. | Study on the Physicochemical Properties of Chitosan and their Applications in the Biomedical Sector | |
| CN113455504B (en) | Chitosan-loaded caffeic acid ester nano-medicament and preparation method and application thereof | |
| CN113845691B (en) | Two-dimensional or three-dimensional cellulose-based porous antibacterial material and preparation method thereof | |
| CN107441494B (en) | Chitosan oligosaccharide and antibiotic with antibacterial film activity and application thereof | |
| Razak et al. | Biotechnological production of fungal biopolymers chitin and chitosan: their potential biomedical and industrial applications | |
| CN115010958A (en) | Hydrogel for promoting wound healing and preparation method and application thereof | |
| CN112500505A (en) | Polymer silver compound and preparation method and application thereof | |
| CN111154010B (en) | Medical cationic polymer biopolymer material, preparation method and application | |
| CN101875704A (en) | Water-soluble chitosan schiff base derivative and preparation method and application thereof | |
| CN108524945B (en) | preparation method of gentamicin modified chitosan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |